Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06881784 · ClinicalTrials.gov registry record · Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT06881784 is a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 420 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06881784, a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Conditions Studied
Interventions
- DRUG daraxonrasib
- DRUG docetaxel
Study Locations (20)
Florida
- Florida Cancer Specialists & Research Institute - South - Fort Myers
- BRCR Global - Plantation
- Cancer Care Centers of Breevard - Rockledge
- Florida Cancer Specialists & Research Institute - North - St. Petersburg
- Cleveland Clinic Martin North - Stuart
- Florida Cancer Specialists & Research Institute - East - West Palm Beach
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Health - Detroit
Alabama
- Alabama Oncology - Birmingham
California
- MemorialCare Long Beach Medical Center - Long Beach
Connecticut
- Yale University, Smillow Cancer Center - New Haven
Georgia
- University Cancer and Blood Center - Athens
Illinois
- Center for Care and Discovery - Chicago
Kansas
- The University of Kansas Cancer Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06881784
The ClinicalTrials.gov registry entry for NCT06881784 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (36% lower). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which daraxonrasib is the first listed.
NCT06881784 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Michigan, Alabama.
Frequently Asked Questions
What is clinical trial NCT06881784 about?
NCT06881784 is a clinical study titled "Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)". The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
What is the current status of trial NCT06881784?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2025-05-06. Estimated completion is 2030-12-01.
What conditions does trial NCT06881784 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma).
What interventions are being tested in trial NCT06881784?
The interventions under investigation include: daraxonrasib (DRUG), docetaxel (DRUG).
Who is sponsoring clinical trial NCT06881784?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06881784 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.